leftspacer middlespacer rightspacer
Media Menu
Featured Material


MAPS BULLETIN
MAPS Bulletin Summer 2014: Research Edition
 
Media > Recent and Archival
August 14, 2014

Psychedelic Drugs Hold Medical Promise

By: Roni Jacobson

Scientific American

Scientific American writes about how the resurgence of research into the therapeutic potential of psychedelics is helping scientists develop new treatments for PTSD, anxiety, depression, OCD, and addiction. Roni Jacobson of Scientific American declares that “Psychedelic drugs are poised to be the next major breakthrough in mental health care.” The article provides details about how the legal classification of psychedelics has hindered psychedelic research for decades, featuring perspective from MAPS and the Drug Policy Alliance about how psychedelic research can become more efficient by changing the way drugs are scheduled by the government.

Donate today to help make psychedelic therapy a legal treatment.


Originally appearing here.

Psychedelic drugs are poised to be the next major breakthrough in mental health care.

Almost immediately after Albert Hofmann discovered the hallucinogenic properties of LSD in the 1940s, research on psychedelic drugs took off. These consciousness-altering drugs showed promise for treating anxiety, depression, post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD) and addiction, but increasing government conservatism caused a research blackout that lasted decades. Lately, however, there has been a resurgence of interest in psychedelics as possible therapeutic agents. This past spring Swiss researchers published results from the first drug trial involving LSD in more than 40 years.

Time for a Psychedelic Spring?

Although the freeze on psychedelic research is thawing, scientists say that restrictive drug policies are continuing to hinder their progress. In the U.S., LSD, psilocybin, MDMA, DMT, peyote, cannabis and ibogaine (a hallucinogen derived from an African shrub) are all classified as Schedule I illegal drugs, which the U.S. Drug Enforcement Administration defines as having a high potential for abuse and no currently accepted medical applications—despite extensive scientific evidence to the contrary. In a joint report released in June, the Drug Policy Alliance and the Multidisciplinary Association for Psychedelic Studies catalogue several ways in which they say that the DEA has unfairly obstructed research on psychedelics, including by overruling an internal recommendation in 1986 that MDMA be placed on a less restrictive schedule.

The DEA and the U.S. Food and Drug Administration maintain that there is insufficient research to justify recategorization. This stance creates a catch-22 by basing the decision on the need for more research while limiting the ability of scientists to conduct that research. The June report recommends transferring responsibility for drug scheduling from the DEA to another agency or nongovernmental organization without a history of antidrug bias, such as the U.S. National Academy of Sciences. No matter how it happens, until the drugs are reclassified, bringing psychedelics from research into clinical practice will be an uphill battle.


Back to MAPS in the Media

Give Our Veterans Hope
1 in 7 Iraq and Afghanistan veterans suffer from PTSD, in many cases leading to suicide. We owe it to our veterans to stop this epidemic.

Tell the Pentagon to fund MAPS' groundbreaking work to treat PTSD.